You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞银下调基石药业(2616.HK)目标价至17.8港元评级“买入”
格隆汇 07-24 12:29

瑞银发表报告,更新对基石药业(02616.HK)的预测,主要由于更新了PD-1抑制剂的行业模型,估计在风险调整基础及稍微降低药物估值之情况下,集团的PD-L1抑制剂的新高峰销售额为40亿元人民币。另外,该行又维持集团主要目标药物高峰销售额达54亿元人民币之预测,并根据海外研发进度提升估值基础。

瑞银表示,基石药业股价表现疲弱,反映近期全球PD-1抑制剂在晚期肝细胞癌(HCC)等疾病上临床失败。该行下调集团股份目标价,由19.71港元降至17.8港元,评级维持“买入”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account